The status of hypertension management in Japan in 2000

Hypertension Research

Volumn 25, Issue 5, 2002, Pages 717-725

  Yamamoto, Yasutaka ^a   Sonoyama, Kazuhiko ^a   Matsubara, Koichi ^a   Furuse, Masako ^a   Yatsuhashi, Toru ^a   Hamada, Toshihiro ^a   Ogino, Kazuhide ^a   Igawa, Osamu ^a   Hisatome, Ichiro ^a   Shigemasa, Chiaki ^a  

^a TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cross sectional survey; Hypertension; JSH 2000; Prescription

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANGIOTENSIN RECEPTOR;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOLOGY; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GROUPS BY AGE; HEART FAILURE; HUMAN; HYPERTENSION; JAPAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PULSE PRESSURE; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; DRUG ANTAGONISM; MIDDLE AGED; PROTEINURIA; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOLOGY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; JAPAN; KIDNEY FAILURE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROTEINURIA; RECEPTORS, ANGIOTENSIN;

EID: 0036747113     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.25.717     Document Type: Article

References (36)

1. Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet 1998; 351: 1755-1762.
2. Amery A, Birkenhager W, Brixko P, et al: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-1354.
3. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
4. Staessen JA, Fagard R, Thijs L, et al: Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-764.
5. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
6. Barry DI, Paulson OB, Jarden JO, Juhler M, Graham DI, Strandgaard S: Effects of captopril on cerebral blood flow in normotensive and hypertensive rats. Am J Med 1984; 76: 79-85.
7. Japan Society of Hypertension Guidelines Subcommittee for the Management Hypertension: Guidelines for the Management of Hypertension for General Practitioners. Hypertens Res 2001; 24: 613-634.
8. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
9. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Education Program Coordinating Committee: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
10. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives: National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension 1999; 34: 1129-1133.
11. Study Group on Long-Term Antihypertensive Therapy: A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension-the GLANT Study. Hypertens Res 1995; 18: 235-244.
12. Ogihara T: Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (the PATE-Hypertension Study) in Japan. Am J Hypertens 2000; 13: 461-467.
13. Kuramoto, K, Matsushita S: The treatment of mild hypertension in the elderly, a prospective study using multiple regression analysis. Jpn Circ J 1985; 49: 1144-1150.
14. Muratani H, Kimura Y, Fukiyama K, et al: Control of blood pressure and lifestyle-related risk factors in elderly Japanese hypertensive subjects. Hypertens Res 2000; 23: 441-449.
15. Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R: Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601-605.
16. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
17. Nilsson P, Andersson DK, Andersson PE, et al: Cardiovascular risk factors in treated hypertensives-a nation-wide, cross-sectional study in Sweden. J Intern Med 1993; 233: 239-245.
18. Primatesta P, Brookes M, Poulter NR: Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001; 38: 827-832.
19. Muratani H, Fukiyama K, Kamiyama T, et al: Current status of antihypertensive therapy for elderly patients in Japan. Hypertens Res 1996; 19: 281-290.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
21. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE Investigators. N Engl J Med 1992; 327: 669-677.
22. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.
23. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
24. Pitt B, Poole-Wilson PA, Segal R, et al: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
25. . Cohn JN: Improving outcomes in congestive heart failure: Val-HeFT: Valsartan in Heart Failure Trial. Cardiology 1999; 91 (Suppl 1): 19-22.
26. Pitt B, Segal R, Martinez FA, et al: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
27. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
28. Wheeldon NM, Viberti GC: Microalbuminuria reduction with valsartan. Am J Hypertens 2001; 14: O-6 (abstract).
29. Cohn JN, Johnson G, Ziesche S, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
30. Dickstein K, Kjekshus J: Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design: Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999; 83: 477-481.
31. Swedberg K, Pfeffer M, Granger C, et al: Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design: Charm-Programme Investigators. J Card Fail 1999; 5: 276-282.
32. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with noninsulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
33. Hansson L, Lindholm LH, Niskanen L, et al: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
34. The EUCLID Study Group: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
35. Australia/New Zealand Heart Failure Research Collaborative Group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380.
36. The Cardiac Insufficiency Bisoprolol Study (CIBIS), CIBIS Investigators and Committees: A randomized trial of beta-blockade in heart failure. Circulation 1994; 90: 1765-1773.